Clinical Trials Logo

Clinical Trial Summary

Medication Overuse Headache (MOH) is an illness affecting about 1,5 % of the general population. It is characterized by chronic headache occurring for at least 15 days a month, by a use of antimigraine drugs during at least 3 months for more than 10 days a month (for ergots, triptans, opiate derivates and combined analgesics) or for more than 15 days a month (for simple analgesics). The chronic headache must have occurred during the period of antimigraine drug abuse and the headache must have returned to its episodical pattern after withdrawal of antimigraine drugs. But, about 50% of the MOH patients will relapse during the first year following the antimigraine drugs withdrawal.

The pathophysiology of MOH is still largely unknown, and the role of antimigraine drug abuse in the transformation from migraine through MOH is not fully understood.


Clinical Trial Description

We recently explored cerebral metabolism in these MOH patients using (18F)FDG-PET (Fluoro Dexoxy Glucose Positon Emission Tomography) comparing them with controls. Results showed a hypometabolism in the OFC, which persist immediately after the antimigraine drugs withdrawal. A similar pattern is observed in varied substance related disorders and should be a marker of addictive behaviour. It can be linked with difficulties in the decision-making process, which can be explored by the Iowa Gambling Task (IGT) test.

Several questions are still unanswered. What will this abnormality become in the long term ? Is it predictive of susceptibility for relapse? Can it be linked to a specific psychological profile (addictive behaviour)? ;


Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research


Related Conditions & MeSH terms


NCT number NCT00833209
Study type Interventional
Source University Hospital, Bordeaux
Contact
Status Completed
Phase N/A
Start date February 2009
Completion date May 2012

See also
  Status Clinical Trial Phase
Completed NCT05720819 - Biofeedback-VR for Treatment of Chronic Migraine N/A
Terminated NCT02583425 - Pilot Study of DFN-11 Injection in Medication Overuse Headache Phase 2
Recruiting NCT03655184 - An Observation Study on Neuropsychology and Serum Melatonin Level in Patients With Medication Overuse Headache
Active, not recruiting NCT02993289 - Is Detoxification Needed in Medication-overuse Headache? N/A
Active, not recruiting NCT05608642 - Intravenous Treatments Used in Medication Overuse Headache Bridge Treatment N/A
Recruiting NCT03671681 - Mindfulness Therapy for Chronic Migraine N/A
Completed NCT01078012 - Short Intervention for Medication Overuse Headache (MOH) - Pilot N/A
Completed NCT03767062 - Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches N/A
Recruiting NCT01754571 - CBT in Patients With Medication Overuse Headache Phase 0
Completed NCT02435056 - Medication Overuse Headache (MOH) and an Innovative Approach N/A
Recruiting NCT05452239 - A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Phase 4
Completed NCT01044251 - Frovatriptan as a Transitional Therapy in Medication Overuse Headache Phase 2
Completed NCT00918671 - Medication-overuse Headache: 4 Years Follow up
Completed NCT04336267 - Anodal tDCS in Chronic Migraine With Medication Overuse N/A
Enrolling by invitation NCT01752439 - Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache N/A
Completed NCT04772742 - Eptinezumab in Adults With Migraine and Medication Overuse Headache Phase 3
Completed NCT04228809 - tDCS in Chronic Migraine With Medication Overuse (Edisom) N/A
Not yet recruiting NCT05334927 - China HeadAche DIsorders RegiStry
Completed NCT04090333 - Endocrinological Profile in Patients With Medication-overuse Headache Before and After Withdrawal Therapy
Recruiting NCT01317992 - Ibudilast in the Treatment of Medication Overuse Headache Phase 1/Phase 2